Abstract |
Abstract Cyclical thrombocytosis, acquired von Willebrand syndrome, aggressive non- melanoma skin cancers and other hydroxyurea complications have been reported in Philadelphia-negative myeloproliferative neoplasms (MPNs), but their incidence and clinical consequences have not been defined in a large cohort of patients. We conducted a retrospective analysis of 188 consecutive patients with MPNs specifically addressing the incidence of these complications. Cyclical thrombocytosis was documented in 29 patients (15%), the majority of whom were receiving hydroxyurea. Acquired von Willebrand syndrome was identified in 17 of the 84 screened patients (20%), but was not associated with any major bleeding complications. Non- melanoma skin cancers were reported in 51 patients (27%). Hydroxyurea-related fever occurred in nine of 149 patients (6%) who received hydroxyurea. Seventy-three patients (39%) experienced a total of 98 major thrombotic events, with the majority of these occurring prior to or within 3 months of the diagnosis. Cyclical thrombocytosis, acquired von Willebrand syndrome, aggressive non- melanoma skin cancers and other hydroxyurea-related complications are not infrequent in MPNs and have important clinical consequences for management.
|
Authors | Emma Verner, Cecily Forsyth, Andrew Grigg |
Journal | Leukemia & lymphoma
(Leuk Lymphoma)
Vol. 55
Issue 5
Pg. 1139-43
(May 2014)
ISSN: 1029-2403 [Electronic] United States |
PMID | 23879199
(Publication Type: Journal Article)
|
Chemical References |
- Janus Kinase 2
- Hydroxyurea
|
Topics |
- Adult
- Aged
- Aged, 80 and over
- Female
- Humans
- Hydroxyurea
(adverse effects, therapeutic use)
- Janus Kinase 2
(genetics)
- Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative
(complications, drug therapy, genetics)
- Male
- Middle Aged
- Myeloproliferative Disorders
- Periodicity
- Platelet Count
- Skin Neoplasms
(diagnosis, etiology)
- Thrombocytosis
(diagnosis, etiology)
- Thrombosis
(etiology)
- von Willebrand Diseases
(diagnosis, etiology)
|